GE Healthcare (NYSE: GE), hailed a new era for breast imaging today as it announced CE marking for SenoClaire *, GE’s new generation of breast tomosynthesis solution designed with a three-dimensional imaging technology. Powered by ASiR *DBT 1, SenoClaire technology uses a low-dose short X-ray sweep around the positioned breast with nine exposures acquired with a “step-and-shoot” method, removing the potential motion from images. “We are thrilled to receive the CE marking for this important product in our Women’s Health business. We continue to innovate our portfolio and aim to help clinicians expand care to more women globally in order to help reduce breast cancer. Our goal was to pioneer an upgrade solution for both our digital mammography platforms, Senographe * Essential and Senographe Care, providing flexibility for customers to enhance their clinical offering for their clinic and patient workflow,” said Prahlad Singh, General Manager, Women’s Health, GE Healthcare - Detection & Guidance Solutions (DGS). More precision, More confidence, Less dose: SenoClaire2 With GE’s SenoClaire, powered by ASiR DBT a single MLO view provides clinical non-inferiority compared to a 2-view digital mammography exam—at half the dose and with just one compression. Subsequently, this solution has the potential to replace digital mammography exams in screening to help radiologists detect breast cancer. In addition, SenoClaire will help deliver superior sensitivity for architectural distortions and masses, help improve specificity of lesion margin visibility, and ultimately, help radiologists reduce recall rates through better characterization of findings. Finally, its images are compatible with major PACS systems, so that radiologists can integrate them easily into their environment and get the most from their investment 3. First shipments have started in Europe, Middle East, Australia and Latin America with a solid flow of customer sites placing orders.